MEDICAGO
Medicago, a biopharmaceutical company headquartered in Quebec City, Canada, today announced Takashi Nagao as the company’s new President and Chief Executive Officer. Prior to becoming President and CEO, Mr. Nagao served as the Chairman of the Board of Medicago, where for the last four years, he has guided Medicago executives to get the company to where it is today.
Medicago, a research and development company for the last 20 years, is embarking on a transformative year, one that will see the company build on its R&D roots to become a company that also produces and commercializes vaccines and other immunotherapies. Mr. Nagao has extensive experience leading pharmaceutical companies through the pre-commercial and commercial process and is well positioned to ensure the successful launch of Medicago’s COVID-19 and influenza vaccines, subject to regulatory approvals. Mr. Nagao will continue Medicago’s evolution towards its goal of being a fully operational commercial entity, able to respond to the needs of the global public health community and medical authorities and professionals.
“Taking on this new role with Medicago during this exciting time is a great honour for me,” said Mr. Nagao, President and Chief Executive Officer, Medicago. “I want our employees, investors, and stakeholders such as the Government of Canada to know that I will put all my efforts into seeing our COVID-19 and influenza vaccines through to a successful launch to protect as many people as possible.”
From 2007 to 2017, Mr. Nagao oversaw the establishment of Mitsubishi Tanabe Pharma Corporation’s U.S. presence and led the team that successfully achieved NDA of RADICAVA®, the first FDA-approved drug in over 20 years for the patients with Amyotrophic Lateral Sclerosis (ALS). Prior to that, Mr. Nagao was a Managing Director in investment banking at J.P. Morgan and Deutsche Bank where he was responsible for global clients and leading equity and cross-border M&A transactions in the pharmaceutical and biotechnology sector in North America, Japan and Europe. He has an MBA from Harvard Business School.
Mr. Nagao succeeds Dr. Bruce D. Clark, who held the position of President and CEO of Medicago since 2017 and was instrumental in the development of Medicago’s COVID-19 vaccine candidate.
Medicago recently announced the start of Phase 2/3 clinical trial of its plant-derived VLP vaccine candidate for COVID-19 to evaluate its efficacy, safety, and immunogenicity, based on the positive Phase 1 results and subsequent allowance to advance to Phase 2/3 by the Canadian regulatory authorities. The company is also building a new facility in Quebec to increase Canada’s domestic capacity for manufacturing vaccines, producing up to a billion doses annually.
“Medicago is at an inflection point. We are moving from a research and development focused organization to become a commercial entity supplying vaccines to Canadians and people around the world,” said Mr. Nagao.
About Medicago
Medicago is a biopharmaceutical company and pioneer in plant-derived therapeutics. Founded in 1999 with the belief that innovative approaches and rigorous research would bring new solutions in healthcare.
Our mission is to improve global health outcomes by leveraging innovative plant-based technologies for rapid responses to emerging global healthcare challenges. Medicago is committed to advancing therapeutics against life-threatening diseases worldwide. Our team includes over 450 scientific experts and employees in Canada and the United States and academic affiliations in Europe and South Africa.
Medicago has previously demonstrated its capability to be a first responder in a flu pandemic. In 2009, the company produced a research-grade vaccine candidate against H1N1 in just 19 days. In 2012, Medicago manufactured 10 million doses of a monovalent influenza vaccine candidate within one month for the Defense Advanced Research Projects Agency (DARPA), part of the U.S. Department of Defense. In 2015, Medicago also demonstrated in principle that it could rapidly produce an anti-Ebola monoclonal antibody cocktail for the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services.
For more information: www.medicago.com
To learn more about our plant-based technology: Video / Website
View source version on businesswire.com: https://www.businesswire.com/news/home/20201204005409/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Signifyd Launches Intelligent Returns to Help Retailers Tackle the Growing Returns Challenge15.9.2025 13:14:00 CEST | Press release
New solutions give retailers faster, safer refund capabilities and the insights needed to reduce the cost of returns Commerce protection provider Signifyd today unveiled Intelligent Returns, a two-solution suite designed to help retailers in the UK and Europe tackle the growing complexity and cost of returns. Consumers are clear about what they expect from retailers and in the UK and EU with consumer rights legislation reinforcing those expectations. A Signifyd survey of thousands of shoppers across the UK, Spain, Italy and France found that 77 percent say return policies strongly influence where they shop, while 94 percent say ease of return is essential. Legal protections, however, often leave retailers with limited flexibility to adjust their policies, making it harder to control costs and abuse without risking customer loyalty. This is especially challenging when fewer than half of consumers say they would buy from a retailer that only offers store credit or charges for returns. Si
Cessna Citation Ascend Program Continues to Advance With Rollout of First Production Unit15.9.2025 13:00:00 CEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, today announced its Cessna Citation Ascend business jet program continues to advance as the first production unit rolled out of the manufacturing facility in Wichita, Kansas. The aircraft is expected to achieve certification from the Federal Aviation Administration later this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915961668/en/ Cessna Citation Ascend program continues to advance with rollout of first production unit (Photo credit: Textron Aviation). Employees held a special celebration to mark the major program milestone of the newest Citation business jet in the legendary 560XL series as they continue to design and deliver the best aviation experience for customers. “Today is a big celebration and thank you to everyone who has been a part of building up to this point. It is your craftsmanship that continues to make milestones like this possible,” sai
Jumpmind Announces Strategic Investment from Lone View Capital15.9.2025 12:00:00 CEST | Press release
The partnership will drive innovation, expand global reach, and reinforce Jumpmind’s position as a leader in next-generation retail software and enterprise data solutions Jumpmind, a leading provider of innovative retail technology solutions, announced today that Lone View Capital (“Lone View”), a growth-oriented private equity firm focused on technology and software investments, has made a strategic investment, acquiring a controlling stake in the company. Founded in 2008, Jumpmind was recently recognized as a Leader in the Forrester Wave™ for Point of Service Solutions (Q4 2024). The company’s flagship product, Jumpmind Commerce, is a cloud-native, microservices-based point of service platform that enables retailers to unify digital and in-store experiences, streamline checkout, and deliver more personalized customer interactions. Trusted by leading retailers worldwide, the platform supports device independence, rapid deployment, and highly configurable customer journeys – empowering
Ookla Launches Speedtest Certified™ to Provide Definitive Network Verification for Properties15.9.2025 12:00:00 CEST | Press release
This new certification provides a trusted badge of excellence for network quality, allowing property owners to validate investments and consumers to identify locations with superior connectivity. Ookla®, a global leader in connectivity intelligence, today announced the launch of Speedtest Certified™, the definitive network connectivity verification program for properties. Leveraging Speedtest®'s globally trusted testing methodology and unrivaled brand recognition, the program answers an increasingly important question: how can property owners prove to consumers that they deliver superior connectivity and are ready to support today's connectivity needs? This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915248087/en/ Pictured is the official plaque awarded to locations that achieve Speedtest Certified™ status, signifying they have met rigorous standards for outstanding network performance. In an era where reliable internet is
The AgreenaCarbon Project Becomes the First Large-Scale Soil Carbon Project to Achieve Verra Verification, Now Issuing 2.3 Million Verified Carbon Credits15.9.2025 10:30:00 CEST | Press release
- The AgreenaCarbon Project has successfully achieved verification under Verra's Verified Carbon Standard VM0042 v2.0 methodology, delivering real, measurable climate impact across millions of hectares - 2.3 million Verified Carbon Units (VCUs) are now being issued, which can be confidently used, tracked, and reported, empowering sustainability teams with compliance-ready results Agreena, the company powering the global transition to regenerative agriculture, has achieved verification of its AgreenaCarbon Project under Verra’s Verified Carbon Standard (VCS) Program’s VM0042 Improved Agricultural Land Management v2.0 methodology – the first large-scale arable agriculture project to do so. By passing this milestone, Agreena is now issuing 2.3 million Verra-verified carbon credits that are not only readily available, but deliver immediate, measurable climate impact. This follows the project’s successful validation in January 2025. While validation confirms that the project design and meth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom